Insight

Joseph Grossman: Botensilimab is effective against Tumors Poorly Responsive to Conventional Immunotherapy

Joseph Grossman/X

Oct 22, 2024, 14:57

Joseph Grossman: Botensilimab is effective against Tumors Poorly Responsive to Conventional Immunotherapy

Joseph Grossman, Vice President of Early Clinical Development at Agenus, shared a post on LinkedIn:

“The final version of our recent Cancer Discovery paper came out today “Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy”.
I couldn’t be prouder of our team at Agenus, or more excited for the future of oncology.”

Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy

Authors: Dhan Chand, et al.

Joseph Grossman

AACR Agenus cancer cancer awareness cancer care Cancer Discovery Dhan Chand fight against cancer Global fight against cancer immunotherapy Joseph Grossman OncoDaily Oncology

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

Special Coverage